Drug intelligence / Profile preview

pravastatin + rosuvastatin

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

A combination of two HMG-CoA reductase inhibitors (statins) that work in the liver to prevent cholesterol from forming, thereby reducing the amount of cholesterol circulating in the blood. This combination is not a standard formulation available as a single pill but rather represents concurrent use of two separate statin medications. Using pravastatin together with rosuvastatin may increase the risk of nerve damage, myopathy, and rhabdomyolysis, which are potential side effects of both medications. Both drugs belong to the statin class and are primarily used to lower lipid levels, including lowering LDL (bad) cholesterol and triglycerides, and raising HDL (good) cholesterol, to reduce the risk of cardiovascular disease including myocardial infarction and stroke. They are considered standard practice following cardiovascular events and for people with moderate to high risk of developing cardiovascular disease.

02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on pravastatin + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pravastatin + rosuvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call